Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals (IONS) Misses A Key Trial Endpoint, Is The Valuation Now Too Harsh?

Ionis Pharmaceuticals (IONS) Misses A Key Trial Endpoint, Is The Valuation Now Too Harsh?

Arrowhead rises on phase III hypertriglyceridemia readout

Needham Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $86

Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug

Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data

Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Ionis Pharmaceuticals Stock Slides 39% Over 9 Straight Down Days